Amneal Pharmaceuticals, Inc. AMRX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s retained earnings?
- Amneal Pharmaceuticals, Inc. (AMRX) reported retained earnings of -$472.75M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s retained earnings changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s retained earnings increased by 20.5% year-over-year, from -$594.87M to -$472.75M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s retained earnings has grown at a 13.3% compound annual growth rate (CAGR), from -$286.82M to -$535.01M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.